These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 20502461)

  • 1. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
    Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
    Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.
    Stingl L; Niewidok N; Müller N; Selle M; Djuzenova CS; Flentje M
    Strahlenther Onkol; 2012 Jun; 188(6):507-15. PubMed ID: 22441439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
    Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
    Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
    Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
    PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
    Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition.
    Schilling D; Garrido C; Combs SE; Multhoff G
    Cancer Lett; 2017 Apr; 390():146-152. PubMed ID: 28108313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
    Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.
    Massey AJ; Schoepfer J; Brough PA; Brueggen J; Chène P; Drysdale MJ; Pfaar U; Radimerski T; Ruetz S; Schweitzer A; Wood M; Garcia-Echeverria C; Jensen MR
    Mol Cancer Ther; 2010 Apr; 9(4):906-19. PubMed ID: 20371713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines.
    Hartmann S; Günther N; Biehl M; Katzer A; Kuger S; Worschech E; Sukhorukov VL; Krohne G; Zimmermann H; Flentje M; Djuzenova CS
    Cancer Lett; 2013 May; 331(2):200-10. PubMed ID: 23340178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
    Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
    McLaughlin M; Barker HE; Khan AA; Pedersen M; Dillon M; Mansfield DC; Patel R; Kyula JN; Bhide SA; Newbold KL; Nutting CM; Harrington KJ
    BMC Cancer; 2017 Jan; 17(1):86. PubMed ID: 28143445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
    Chen MH; Lin KJ; Yang WL; Kao YW; Chen TW; Chao SC; Chang PM; Liu CY; Tzeng CH; Chao Y; Chen MH; Yeh CN; Huang CY
    Cancer; 2013 Jan; 119(2):293-303. PubMed ID: 22810956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of hsp90 compromises the DNA damage response to radiation.
    Dote H; Burgan WE; Camphausen K; Tofilon PJ
    Cancer Res; 2006 Sep; 66(18):9211-20. PubMed ID: 16982765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.